Phase 3 Eczema Trial, Recruiting NCT07592585 Sponsor: Jiangsu vcare pharmaceutical technology co., LTD Condition: Eczema
Back to Eczema

Phase 3 Eczema Trial, Recruiting

NCT07592585
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who fully understand the study, are willing to follow the trial procedures, and agree to sign a consent form
  • People who are 12 years of age or older, of any gender, at the time of signing the consent form
  • People who have been diagnosed with atopic dermatitis (eczema) according to a standard set of medical diagnostic criteria called the Hanifin-Rajka criteria

Who may not be able to join:

  • People whose atopic dermatitis has been considered unstable by the study doctor in the two weeks before the study start — for example, if the condition has been clearing up on its own or getting worse very quickly
  • People whose skin symptoms at the time of screening and study start are only on the hands or feet, with no history of symptoms in other typical areas such as the face or skin folds
  • People who have skin damage or differences in the affected area — such as significant scarring, tattoos, or changes in skin colour — that could make it difficult to assess the study treatment's effects
  • People who have other skin conditions at the time of screening and study start that could affect how the treatment is assessed, such as psoriasis, acne, skin cancer, widespread redness of the skin, or Netherton syndrome

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: qianjin Lu, Chinese Academy of Medical Sciences Hospital for Skin Disease

Phone: +8615358160458

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Registry
ClinicalTrials.gov
Start date
12 May 2026
Est. completion
30 May 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of subjects achieving an Investigator's Global Assessment (IGA) response (defined as an IGA score of 0 or 1 with a reduction of ≥2 points from baseline)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov